Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery
TipRanksApr 8 18:25
Verve Therapeutics Analyst Ratings
BenzingaApr 3 20:45
Buy Rating Affirmed for Verve Therapeutics With Strategic Focus on Promising VERVE-102 Program
TipRanksApr 3 06:25
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Clinical Studies and Strategic Advancements
TipRanksFeb 29 04:25
Verve Therapeutics Analyst Ratings
BenzingaFeb 28 23:46
RBC Capital Sticks to Their Buy Rating for Verve Therapeutics (VERV)
TipRanksFeb 28 20:16
RBC Capital Remains a Buy on Verve Therapeutics (VERV)
TipRanksNov 9, 2023 09:46
Verve Therapeutics' Robust Financial Performance and Promising Future Prospects: A Buy Rating Justified
TipRanksNov 8, 2023 20:46
Analysts' Top Healthcare Picks: Vigil Neuroscience Inc (VIGL), Verve Therapeutics (VERV)
TipRanksNov 7, 2023 23:00
Strong Buy Rating for Verve Therapeutics: Influenced by Eli Lilly's Acquisition, Partnership Prospects, and Positive FDA Clearance
TipRanksOct 31, 2023 22:46
Positive Prospects for Verve Therapeutics: FDA Approval, Innovative Treatment and Promising Preliminary Data Drive Buy Rating
TipRanksOct 24, 2023 18:40
Analysts' Top Healthcare Picks: Verve Therapeutics (VERV), Immunovant (IMVT)
TipRanksOct 24, 2023 18:40
Promising Future of Verve Therapeutics: A Comprehensive Analysis Supporting the Buy Rating
TipRanksOct 24, 2023 04:45
Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target
BenzingaSep 13, 2023 20:49
Verve Therapeutics Analyst Ratings
BenzingaSep 13, 2023 20:26
Cantor Fitzgerald Keeps Their Hold Rating on Verve Therapeutics (VERV)
TipRanksAug 30, 2023 14:05
Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target
BenzingaAug 30, 2023 00:04
Verve Therapeutics Analyst Ratings
BenzingaAug 30, 2023 00:03
Analysts' Opinions Are Mixed on These Healthcare Stocks: Replimune Group (REPL) and Verve Therapeutics (VERV)
TipRanksAug 18, 2023 20:11
Guggenheim Maintains Buy on Verve Therapeutics, Lowers Price Target to $55
BenzingaAug 15, 2023 23:09
No Data
No Data